Novo Investors Seek Clarity on Wegovy Weight-Loss Drug Shortages

When Novo Nordisk publishes third-quarter results next week investors and analysts are hoping the company will clarify when limits on the supply of starter doses of its weight-loss drug Wegovy in the United States will cease.
Reuters Health Information

source https://www.medscape.com/s/viewarticle/997802?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?